Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Cancer Discov. 2016 Sep 7;6(10):1134–1147. doi: 10.1158/2159-8290.CD-16-0305

Figure 3. PIM1 confers resistancethrough activating common downstream pathways of AKT in the presence of PI3K inhibition.

Figure 3

A. T47D cells expressing GFP or PIM1 were treated with the indicated inhibitors (each at 1μM concentration) for 24 hours, and cell lysates were prepared for immunoblotting for the indicated proteins. B. T47D cells expressing GFP, PIM1, or myrAKT were treated with the indicated inhibitors (BYL719 at 0, 0.3, and 1μM, LGH447 at 1μM) for 24 hours, and cell lysates were prepared for immunoblotting for the indicated proteins. C. T47D cells with indicated treatment were fixed in ethanol for cell cycle analysis. Percent of S phase cells were shown. Mean and SE of three replicates are shown. ** indicates p<0.01. D. T47D cells cultured to resistance in the presence of BYL719. Both parental (T47D) and resistant (T47DR) cells were treated with BYL719 at 1μM, and cell lysates were prepared at 0, 4, 24 hours for immunoblotting for the indicated proteins.